Table 1.
Means and frequencies of participants’ characteristics by androgen receptor status (N=1467), Nurses’ Health Study (1976–1997)
Characteristic | AR− | AR+ |
---|---|---|
N (%) | 313 (21.3) | 1154 (78.7) |
Age at diagnosis, mean (N), yr | 59.0 (313) | 60.8 (1154) |
BMI at diagnosis, mean (N*), kg/m2 | 26.6 (280) | 26.0 (1041) |
Smoking, N* (%) | ||
Never | 138 (44.2) | 442 (38.5) |
Past | 125 (40.1) | 482 (42.1) |
Current | 49 (15.7) | 222 (19.4) |
ER status, N (%) | ||
Positive | 140 (44.7) | 1024 (88.7) |
Negative | 173 (55.3) | 130 (11.3) |
PR status, N* (%) | ||
Positive | 114 (36.7) | 830 (72.2) |
Negative | 197 (63.3) | 319 (27.8) |
HER2 status, N* (%) | ||
Positive | 46 (15.0) | 81 (7.1) |
Negative | 260 (85.0) | 1059 (92.9) |
Nodal involvement, N (%) | ||
None | 212 (67.7) | 883 (76.5) |
1 – 3 | 78 (24.9) | 220 (19.1) |
4 – 9 | 16 (5.1) | 28 (2.4) |
≥ 10 | 7 (2.3) | 23 (2.0) |
Tumor size (cm), N (%) | ||
≤ 2 | 188 (60.1) | 814 (70.5) |
> 2 | 125 (39.9) | 340 (29.5) |
Histological grade, N (%) | ||
I (low) | 22 (7.0) | 302 (26.2) |
II (intermediate) | 127 (40.6) | 692 (60.0) |
III (high) | 164 (52.4) | 160 (13.8) |
Stage†, N (%) | ||
I | 154 (49.2) | 682 (59.1) |
II | 126 (40.3) | 394 (34.1) |
III | 33 (10.5) | 78 (6.8) |
Chemotherapy, N* (%) | ||
Yes | 141 (55.7) | 258 (27.4) |
No | 112 (44.3) | 682 (72.6) |
Hormone treatment, N* (%) | ||
Yes | 145 (58.2) | 672 (71.3) |
No | 104 (41.8) | 270 (28.7) |
Radiation treatment, N* (%) | ||
Yes | 114 (45.4) | 393 (41.6) |
No | 137 (54.6) | 551 (58.4) |
N doesn’t add to total because of missing information.
Stage I=tumor size<=2cm and no nodal involvement;
II=tumor size<=2cm & 1–3 nodes or 2–4cm & 0–3 nodes or 4+cm & 0 nodes;
III=tumor size<=2cm & 4+ nodes or 2–4cm & 4+ nodes or >4cm & 1+ nodes.